November 26, 2018 / 5:08 PM / 13 days ago

BRIEF-FDA Approves Actpen For Genentech's Actemra

Nov 26 (Reuters) - GENENTECH:

* FDA APPROVES THE ACTPEN FOR GENENTECH’S ACTEMRA, A SINGLE-DOSE, PREFILLED AUTOINJECTOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS, GIANT CELL ARTERITIS AND TWO FORMS OF JUVENILE ARTHRITIS

* GENENTECH SAYS ACTPEN IS EXPECTED TO BE AVAILABLE IN JANUARY 2019. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below